143 related articles for article (PubMed ID: 38367684)
1. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs.
Wang Z; Ramakrishna R; Wang Y; Qiu Y; Ma J; Mintzlaff D; Zhang H; Li B; Hammell B; Lucia MS; Pomfret E; Su AA; Washington KM; Mathes DW; Wang Z
Eur J Pharmacol; 2024 Apr; 968():176408. PubMed ID: 38367684
[TBL] [Abstract][Full Text] [Related]
2. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
3. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.
Wang H; Wang Z; Zhang H; Qi Z; Johnson AC; Mathes D; Pomfret EA; Rubin E; Huang CA; Wang Z
Mol Oncol; 2020 May; 14(5):991-1000. PubMed ID: 32107846
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
5. Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Navarro-Alvarez N; Shah JA; Zhang H; Huang Q; Zheng Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Vet Immunol Immunopathol; 2016 Dec; 182():150-158. PubMed ID: 27863545
[TBL] [Abstract][Full Text] [Related]
6. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4
Wang Z; Louras NJ; Lellouch AG; Pratts SG; Zhang H; Wang H; Huang CA; Cetrulo CL; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2018 Aug; 12(8):1374-1382. PubMed ID: 29873181
[TBL] [Abstract][Full Text] [Related]
7. Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Pratts SG; Zhang H; Spencer PJ; Yu R; Tonsho M; Shah JA; Tanabe T; Powell HR; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2016 Apr; 10(4):553-65. PubMed ID: 26643572
[TBL] [Abstract][Full Text] [Related]
8. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
9. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.
Han T; Abdel-Motal UM; Chang DK; Sui J; Muvaffak A; Campbell J; Zhu Q; Kupper TS; Marasco WA
PLoS One; 2012; 7(9):e44455. PubMed ID: 22973452
[TBL] [Abstract][Full Text] [Related]
10. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
13. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Huang L; He H; Wang K; Ma X; Chen X; Chen W; Wang X; Jiang X; Feng M
Biomed Pharmacother; 2022 Nov; 155():113659. PubMed ID: 36095959
[TBL] [Abstract][Full Text] [Related]
14. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
15. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
[TBL] [Abstract][Full Text] [Related]
16. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
17. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
Francisco JA; Schreiber GJ; Comereski CR; Mezza LE; Warner GL; Davidson TJ; Ledbetter JA; Siegall CB
Blood; 1997 Jun; 89(12):4493-500. PubMed ID: 9192773
[TBL] [Abstract][Full Text] [Related]
19. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]